Theranos – Perspectives From “Last Chance” Turnaround

Date: Wednesday, October 23, 2019
Time: 6:00pm-8:30pm
Location: Pillsbury Winthrop Shaw Pittman LLP
2550 Hanover Street
Palo Alto, CA 94304


Register

 

Sponsored by

 

Aspects of the Theranos story have been covered extensively by the media. What happened in the last 2 years of the company’s life is fascinating but lesser known. A revamped Board and leadership team tried to turn the company around in the face of critical capital needs, mounting litigation and market pressures.

Please join ACGSV for a fireside discussion as the former CFO shares his perspectives with Tom Thomas, Partner at Pillsbury Winthrop Shaw Pittman LLP.

 

Our Distinguished Panel

 

Philippe Poux

Former Interim CFO
Theranos

Philippe Poux was Theranos’ interim CFO for the last twelve months of its life. He has been living in Silicon Valley since 2010 and worked as CFO of several technology startups. He was previously at AREVA, a large European clean energy equipment manufacturer, as head of M&A and CFO of a brand-new division he helped create by acquiring technology companies around the world. Prior to Areva, Philippe spent a number of years in transaction advisory at Ernst & Young, as well as eight years consulting with Booz & Co. in both Paris and Chicago. He holds an MBA from Chicago Booth School of Business.

 

Tom Thomas

Partner
Pillsbury

Tom Thomas practices primarily in the area of corporate finance and governance, mergers and acquisitions, technology transactions and executive compensation. He leads the firm’s Venture Capital practice.

Tom represents companies at all stages of development. His practice focuses on corporate matters including debt and equity offerings; public and private acquisitions and dispositions; venture capital financings and investments; joint ventures and strategic alliances; and SEC compliance and reporting. Tom also has extensive experience in licensing, distribution and other technology transactions; lending and going-private transactions; PIPE offerings; commercial contracts; board governance and support; disclosure obligations; equity compensation matters; and day-to-day general corporate matters.

 

Register